Schedule 13D/G History
Ownership

Frazier Life Sciences Public Fund, L.P. - Significant Ownership

Signature - Title: Frazier Life Sciences Public Fund, L.P. - Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Location: Palo Alto, CA
Summary: This page shows a list of all the recent SCHEDULE 13D/G filings made by Frazier Life Sciences Public Fund, L.P..

Significant Ownership of Frazier Life Sciences Public Fund, L.P.

Sym	Company	Class	Ownership	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
TRVI	Trevi Therapeutics, Inc.	Common Stock	11.9%	$64.7M		10.7M		James N. Topper	Dec 31, 2024
MAZE	Maze Therapeutics, Inc.	Common Stock, par value $0.001 per share	7.3%	$36.1M		3.19M		James N. Topper	Feb 3, 2025
MREO	Mereo BioPharma Group plc	Ordinary Shares, nominal value EURO0.003 per share, represented by American Depository Shares	5.1%	$101M		40.3M		James N. Topper	Apr 1, 2025
PVLA	Palvella Therapeutics, Inc.	Common Stock	5.1%	$16.7M		576K		James N. Topper	Dec 13, 2024
ELDN	Eledon Pharmaceuticals, Inc.	Common Stock	2%	$5.53M		1.18M		James N. Topper	Dec 31, 2024
ANAB	AnaptysBio, Inc.	Common Stock	0.5%					Frazier Life Sciences Public Fund, L.P.	Jan 31, 2025
ANTX	AN2 THERAPEUTICS, INC.	Common Stock	0%	$0		0		Frazier Life Sciences Public Fund, L.P.	Dec 31, 2024
PBYI	Puma Biotechnology, Inc.	Common Stock	0%	$0		0		Frazier Life Sciences Public Fund, L.P.	Dec 31, 2024

Showing 1 to 8 of 8 entries

Schedules 13D/G Reported by Frazier Life Sciences Public Fund, L.P.:

Showing 0 to 0 of 0 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.